Home    Back

Vsl#3    (DrugBank: -)

3 diseases
IDDisease name (Link within this page)Number of trials
96Crohn disease7
97Ulcerative colitis3
291Hirschsprung disease, entire colon type1

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
7 / 2,209 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01765439
(ClinicalTrials.gov)		February 20147/1/2013The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel DiseaseThe Effect of VSL#3 (Original De Simone Formulation) Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel DiseaseCrohn Disease;Ulcerative ColitisDietary Supplement: VSL#3 (Original De Simone formulation)Charles University, Czech RepublicIscare i.v.f., Czech Republic;CD Investments srl;University Of Perugia;University of Roma La SapienzaActive, not recruitingN/AN/AAll79N/ACzechia;Czech Republic
2NCT01632462
(ClinicalTrials.gov)		September 201225/6/2012A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's DiseaseA Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's DiseaseCrohn's DiseaseDrug: VSL#3Federico II UniversityNULLRecruiting5 Years17 YearsBoth30Phase 4Italy
3NCT01548014
(ClinicalTrials.gov)		January 201017/2/2012The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's DiseaseReduction in Frequency of Infliximab Administration From q 8 Weeks to q 12 Weeks in Children With Crohn's Disease Receiving Probiotic VSL#3 Supplementation: A Pilot StudyCrohn's DiseaseDietary Supplement: VSL#3Samsung Medical CenterNULLRecruiting13 Years17 YearsBoth1Phase 3Korea, Republic of
4NCT00367705
(ClinicalTrials.gov)		August 200922/8/2006VSL#3 Treatment in Children With Crohn's DiseaseDouble-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's DiseaseCrohn's DiseaseDietary Supplement: VSL#3®;Dietary Supplement: PlaceboHadassah Medical OrganizationNULLNot yet recruiting6 Years18 YearsBoth300Phase 4Israel
5NCT00944736
(ClinicalTrials.gov)		July 200922/7/2009Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's DiseaseEffect of Probiotic VSL#3 on Intestinal Permeability of Pediatric Patients With Crohn's Disease in RemissionCrohn's DiseaseDietary Supplement: VSL#3;Dietary Supplement: PlaceboChildren's Mercy Hospital Kansas CityVSL PharmaceuticalsCompleted11 Years17 YearsBoth12Phase 3United States
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT00114465
(ClinicalTrials.gov)		June 200514/6/2005VSL#3 Versus Placebo in Maintenance of Remission in Crohn's DiseaseRandomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's DiseaseCrohn's DiseaseDrug: VSL#3;Other: PlaceboOrphan AustraliaNULLCompleted18 Years75 YearsBoth38Phase 4Australia
7NCT00175292
(ClinicalTrials.gov)		December 200313/9/2005A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.A Randomized and Placebo-Controlled Double-Blind Multicentre Study to Determine the Efficacy and Safety of VSL#3 Probiotic Food Supplement Mixture in Prevention of Endoscopic Recurrence in Crohn's Disease Patients With Ileocolonic Surgical Resection and Small Intestine to Colon Anastomosis.Crohn's Disease;Inflammatory Bowel DiseaseDrug: Probiotic - VSL#3University of AlbertaCanadian Institutes of Health Research (CIHR)Completed16 YearsN/ABoth120Phase 3Canada

Back to top


97. Ulcerative colitis    [ 2,269 clinical trials,   1,331 drugs,   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways]
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 2,269 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03415711
(ClinicalTrials.gov)		April 28, 20175/1/2018PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative ColitisA Double-blind, Randomized, Placebo-controlled, Single-center, Dose-finding, Pilot Study Evaluating the Efficacy of VSL#3® in the Maintenance of Clinical and Endoscopic Remission of Mild-to-moderate UCUlcerative ColitisDietary Supplement: VSL#3®;Drug: Mesalamine;Drug: PlaceboVSL PharmaceuticalsActial Farmaceutica S.r.l.Terminated18 Years85 YearsAll14N/AItaly
2NCT01765439
(ClinicalTrials.gov)		February 20147/1/2013The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel DiseaseThe Effect of VSL#3 (Original De Simone Formulation) Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel DiseaseCrohn Disease;Ulcerative ColitisDietary Supplement: VSL#3 (Original De Simone formulation)Charles University, Czech RepublicIscare i.v.f., Czech Republic;CD Investments srl;University Of Perugia;University of Roma La SapienzaActive, not recruitingN/AN/AAll79N/ACzechia;Czech Republic
3NCT00951548
(ClinicalTrials.gov)		October 20062/8/2009Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative ColitisFood Supplementation With the Probiotic Preparation VSL#3 as a Support to Standard Pharmaceutical Therapy in Patients With Mild to Moderate Active Ulcerative Colitis. A Double-blind, Randomized, Placebo Controlled StudyUlcerative ColitisDietary Supplement: VSL#3;Dietary Supplement: PlaceboVSL PharmaceuticalsNULLCompleted18 YearsN/ABoth144N/AItaly

291. Hirschsprung disease, entire colon type    [ 13 clinical trials,   32 drugs,   (DrugBank: 15 drugs),   0 drug target gene,   0 drug target pathway]
Searched query = "Hirschsprung disease, entire colon type", "Hirschsprung disease, small intestine type", "Hirschsprung disease", "Hirschprung disease", "Hirschsprung disease associated entercolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 13 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00630838
(ClinicalTrials.gov)		September 200628/2/2008Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)Hirschsprung DiseaseDrug: VSL#3;Drug: PlaceboUniversity of MichiganNULLCompleted1 Month12 MonthsAll62Phase 2United States

Back to top